Analytical Data
-
Gene name
BIRC8
- Application
-
Alternative Names
BIRC8；ILP2；Baculoviral IAP repeat-containing Protein 8
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q96P09
-
Expression Region
1-236aa
-
AA Sequence
MTGYEARLITFGTWMYSVNKEQLARAGFYAIGQEDKVQCFHCGGGLANWKPKEDPWEQHAKWYPGCKYLLEEKGHEYINNIHLTRSLEGALVQTTKKTPSLTKRISDTIFPNPMLQEAIRMGFDFKDVKKIMEERIQTSGSNYKTLGVLVADLVSAQKDTTENELNQTSLQREISPEEPLRRLQEEKLCKICMDRHIAVVFIPCGHLVTCKQCAEAVDRCPMCSMVIDFKQRVFMS
-
Molecular Weight
54.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BIRC8, also known as Baculoviral IAP Repeat Containing 8, is a member of the inhibitor of apoptosis (IAP) protein family, which plays a crucial role in regulating apoptosis and cellular survival. Research into BIRC8 has gained significant interest due to its involvement in various cellular processes, including cell cycle regulation, immune response modulation, and the development of several types of cancer. Overexpression of BIRC8 has been linked to tumor progression and resistance to chemotherapy, making it a potential target for cancer therapeutics. Scientists are increasingly focused on understanding the specific mechanisms by which BIRC8 regulates apoptosis and its interactions with other signaling pathways. Additionally, the study of BIRC8 has implications for the development of biomarker assays and targeted therapies, as modulating its activity could restore apoptotic pathways in cancer cells. Recombinant BIRC8 protein is being produced for structural and functional studies, which may yield insights into its role in cancer and provide a foundation for novel therapeutic approaches. Understanding BIRC8's function at the molecular level could lead to breakthroughs in treating apoptotic-related diseases, emphasizing its importance in the field of cancer biology and therapeutic development. Additionally, targeting BIRC8 may complement existing therapies, enhancing treatment efficacy and overcoming drug resistance in cancer patients. Overall, BIRC8 represents a compelling focus for ongoing research, with the potential to contribute significantly to therapeutic innovations in oncology.
